Abstract 291

Lenalidomide (L) is an immunomodulatory agent with therapeutic activity in CLL; rituximab (R), a CD20 mAb, has limited activity as monotherapy in CLL. In preclinical models, L resulted in NK cell expansion and synergized with R. Therefore, a phase II, 2-stage study was designed to evaluate this combination. Treatment-naïve patients (pts) were eligible if they had an indication for therapy, normal kidney function, and no history of deep vein thrombosis or pulmonary embolic events.

Pts started L at 2.5 mg per day (D) and could escalate to 5 mg/D on D8 and again on C3D1 to a maximum of 10 mg/D if tolerated. Pts received L 21 of 35 D for cycle (C) 1, then for 21/28 D for C2-7 (7 cycles total). R was started at the end of C1 at 50 mg/m2 D29, 325 mg/m2 D31, 375 mg/m2 D33, C1, then 375 mg/m2 weekly × 4 for C2 and on D1 for C3-7. Pts received allopurinol 300 mg daily, and following a protocol amendment, aspirin at 81 mg daily.

The study has closed to accrual with 69 pts enrolled at four CRC clinical sites. 40 pts enrolled into arm A (age under 65). 29 in arm B (age 65 or older). 57 now have final response data.

The median age on arm A was 57 years (range 45–64) and arm B 70 years (range 65–80). Advanced Rai stage (III-IV) was present at baseline more frequently in arm B pts (48%) compared to arm A pts (23%) (p= 0.04). 73% of pts on arm A had an excellent performance status (ECOG 0/5) compared to only 54% of pts on arm B. Arm A pts frequently had aggressive leukemia features including unmutated IgVH genes and/or elevated CLL expression of ZAP-70 in 70%, these features were present in 52% of those on arm B. 4 pts on arm A and 2 on arm B had del(17p) by FISH whereas 5 pts in arm A and 4 in arm B had del(11q).

A significantly lower proportion of pts on arm B (16/27) were able to complete the 7 cycles of therapy compared to (35/39) of eligible pts on arm A (p=0.013) mainly due to toxicity. Similarly, older patients were limited in dose escalation or maintenance of the maximum L dose (10 mg). 27/39 pts on arm A achieved a median L dose of 10 mg while only 13/27 pts on arm B tolerated the 10 mg L dose.

The most frequent and severe adverse events (AEs) are summarized in Table 1. Infusion and tumor flare reactions (TFR) were observed more frequently during cycle 1 than in subsequent cycles. Neutropenia was frequently grade (G) 3/4 in severity. Severe (G3/4) AEs were reported in 72% of arm A pts and 82% of pts on arm B (p =.55), with non-heme G3/4 toxicities reported in 37% of arm A and 52% of arm B (p =.31).

Table 1
Frequent and Severe AEsArm A
Arm B
GradeI/IIIII/IVI/IIIII/IV
TFR 32 – 16 
Neutropenia 11 19 15 
Anemia 15 14 
Thrombocytopenia 21 13 
Fatigue 25 – 14 
AST/ALT elevation 18 11 
Hypophosphatemia 19 
Hypocalcemia 21 – 15 – 
Infusion Reaction 20 – 
Respiratory Infection 17 – – 
Pneumonia – 
Rash 14 12 
Neutropenic Fever – – 
PE/DVT – – – 
Frequent and Severe AEsArm A
Arm B
GradeI/IIIII/IVI/IIIII/IV
TFR 32 – 16 
Neutropenia 11 19 15 
Anemia 15 14 
Thrombocytopenia 21 13 
Fatigue 25 – 14 
AST/ALT elevation 18 11 
Hypophosphatemia 19 
Hypocalcemia 21 – 15 – 
Infusion Reaction 20 – 
Respiratory Infection 17 – – 
Pneumonia – 
Rash 14 12 
Neutropenic Fever – – 
PE/DVT – – – 

Responses are summarized in Table 2. The overall response rate (ORR) to therapy for arm A was 94%, 90% CI (83%, 99%) with 20% (10%, 34%) achieving a complete remission (CR) and 17% a nodular PR (nPR). The ORR for arm B was 77% with 90% CI (58%, 91%) with 9% (2%, 26%) achieving a CR. Arm A patients had median follow-up of 17 months (from D 1 of treatment) with an estimated median progression free survival of 19 months. Arm B had a median follow-up of 7 months, with an estimated 85% remaining progression free at 7 months.

Table 2
ResponsesArm A (Age < 65) N = 35
Arm B (Age >= 65) N = 22
NCR N (%)nPR N (%)PR N (%)ORR N (%)NCR N (%)PR N (%)ORR N (%)
All patients 35 7 (20) 6 (17) 20 (57) 33 (94) 22 2 (9) 15 (68) 17 (77) 
IgVH unmutated 22 4 (18) 2 (9) 15 (68) 21 (96) 13 1 (8) 10 (77) 11 (85) 
IgVH mutated 13 3 (23) 4 (31) 5 (38) 12 (92) 1 (11) 5 (56) 6 (67) 
Median L dose 10 mg 24 7 (29) 5 (21) 12 (50) 24 (100) 2 (25) 5 (63) 7 (88) 
Rai stage III/IV 2 (22) 1 (11) 5 (56) 8 (89) 11 1 (9) 6 (55) 7 (64) 
17p del 2 (67) 2 (67) 
11q del 1 (33) 2 (67) 3 (100) 3 (75) 3 (75) 
TFR present 28 5 (18) 5 (18) 16 (57) 26 (93) 14 11 (79) 11 (79) 
ResponsesArm A (Age < 65) N = 35
Arm B (Age >= 65) N = 22
NCR N (%)nPR N (%)PR N (%)ORR N (%)NCR N (%)PR N (%)ORR N (%)
All patients 35 7 (20) 6 (17) 20 (57) 33 (94) 22 2 (9) 15 (68) 17 (77) 
IgVH unmutated 22 4 (18) 2 (9) 15 (68) 21 (96) 13 1 (8) 10 (77) 11 (85) 
IgVH mutated 13 3 (23) 4 (31) 5 (38) 12 (92) 1 (11) 5 (56) 6 (67) 
Median L dose 10 mg 24 7 (29) 5 (21) 12 (50) 24 (100) 2 (25) 5 (63) 7 (88) 
Rai stage III/IV 2 (22) 1 (11) 5 (56) 8 (89) 11 1 (9) 6 (55) 7 (64) 
17p del 2 (67) 2 (67) 
11q del 1 (33) 2 (67) 3 (100) 3 (75) 3 (75) 
TFR present 28 5 (18) 5 (18) 16 (57) 26 (93) 14 11 (79) 11 (79) 

A defined course of seven cycles of L and R administered for the initial treatment of CLL was associated with a high response rate (ORR 88%) with 16% CRs and 11% nPRs. Older patients were more likely to have advanced Rai stage at baseline and were less likely to escalate or maintain the maximum L dose and/or complete the 7 cycles of therapy, factors that may have contributed to a lower CR, and ORR rate in arm B. An additional 11 patients will have final response assessments by October 2011.

Disclosures:

James:Celgene: Honoraria, Research Funding. Off Label Use: Lenalidomide for Chronic lymphoyctic leukemia. Brown:Calistoga: Consultancy; Pharmacyclics: Consultancy; Celgene: Consultancy, Research Funding; Genzyme: Research Funding. Rai:Celgene: Membership on an entity's Board of Directors or advisory committees. Neuberg:Celgene: Research Funding. Kipps:Igenica: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Abbott Industries: Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; GSK: Research Funding; Gilead Sciences: Consultancy, Research Funding; Amgen: Research Funding.

Author notes

*

Asterisk with author names denotes non-ASH members.

This icon denotes a clinically relevant abstract

Sign in via your Institution